Compare SLS & LATA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLS | LATA |
|---|---|---|
| Founded | 2012 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.0M | 229.1M |
| IPO Year | N/A | 2025 |
| Metric | SLS | LATA |
|---|---|---|
| Price | $3.51 | $10.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 8.3M | 55.0K |
| Earning Date | 03-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $9.92 |
| 52 Week High | $5.18 | $10.20 |
| Indicator | SLS | LATA |
|---|---|---|
| Relative Strength Index (RSI) | 45.61 | 69.61 |
| Support Level | $3.66 | $10.02 |
| Resistance Level | $4.20 | $10.09 |
| Average True Range (ATR) | 0.42 | 0.02 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 1.48 | 100.00 |
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Galata Acquisition Corp II is a blank check company.